Palisade Bio_Logos(4.22)VSM.png
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
01 mai 2024 08h30 HE | Palisade Bio, Inc.
Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end Carlsbad, CA, May 01, 2024 (GLOBE NEWSWIRE) -- Palisade...
logo.png
Nanomix Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples
26 mai 2022 08h30 HE | Nanomix Corporation
EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics,...